Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients

Upsala Journal of Medical Sciences

Volumn 115, Issue 4, 2010, Pages 232-237

  Yang, Meisongzhu ^a,b   Chen, Gang ^b   Dang, Yiwu ^b   Luo, Dianzhong ^b  

^a JISHOU UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Decoy receptor 3 (DcR3); enzyme linked immunosorbent assay (ELISA); hepatocellular carcinoma (HCC); immunohistochemistry (IHC)

Indexed keywords

DECOY RECEPTOR 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CHOLECYSTITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHOLECYSTITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 77958530304     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2010.516410     Document Type: Article

References (17)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.
2. Jaeck D, Bachellier P, Oussoultzoglou E, Weber JC, Wolf P. Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver Transpl. 2004;10: S58-63.
3. Orito E, Mizokami M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. Hepatol Res. 2007;37: S33-5.
4. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62-5.
5. Nagai H, Sumino Y. Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Patents Anticancer Drug Discov. 2008;3:220-6.
6. Colombo M. Screening for cancer in viral hepatitis. Clin Liver Dis. 2001;5:109.
7. Sherman M. Alphafetoprotein: An obituary. J Hepatol. 2001;34:603-5.
8. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer. 2003;105:724-32.
9. Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia. 2008;10:1049-56.
10. Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007;106:112-8.
11. Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol. 2008;111:330-5.
12. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102:26-38.
13. Chen G, Luo D. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci. 2008;113:297-304.
14. Chen G, Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India. 2008;21:275-8.
15. Shen HW, Gao SL, Wu YL, Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol. 2005;11:5926-30.
16. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699-703.
17. Hwang SL, Lin CL, Cheng CY, Lin FA, Lieu AS, Howng SL, et al. Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery. Kaohsiung J Med Sci. 2004;20:124-7.